Literature DB >> 34155345

OGT regulated O-GlcNAcylation promotes papillary thyroid cancer malignancy via activating YAP.

Xiaoyan Li1, Zhengming Wu2, Jing He1, Yiting Jin1, Chengyu Chu1, Yun Cao1, Fei Gu1, Hongying Wang1, Chenjian Hou3, Xiuping Liu4,5, Qiang Zou6.   

Abstract

The incidence of thyroid cancer is growing rapidly during the past decades worldwide. Although most thyroid tumors are curable, some patients diagnosed with distant metastases are associated with poor prognosis. The molecular mechanisms underlying these cases are still largely unknown. Here we found that the upregulated O-Linked N-Acetylglucosamine Transferase (OGT) expression and O-GlcNAcylation (O-GlcNAc) modification in papillary thyroid cancer (PTC) were essential in tumor growth and metastasis. Mass spectrometry analysis showed that YAP was the effector protein modified by OGT. In details, YAP Ser109 O-GlcNAcylation promoted the malignant phenotypes in PTC cells by inducing YAP Ser127 dephosphorylation and activation. Our work clearly showed the critical role of OGT and YAP played in PTC tumors and made it possible for us to seek the clinical potential of manipulating OGT/YAP activity in PTC targeted therapies. These findings also confirmed OGT worked in collaboration with classical Hippo pathway kinases as an upstream regulator of YAP in PTC tumors.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34155345     DOI: 10.1038/s41388-021-01901-7

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  50 in total

1.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

Review 2.  The intersections between O-GlcNAcylation and phosphorylation: implications for multiple signaling pathways.

Authors:  Quira Zeidan; Gerald W Hart
Journal:  J Cell Sci       Date:  2010-01-01       Impact factor: 5.285

3.  Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013.

Authors:  Hyeyeun Lim; Susan S Devesa; Julie A Sosa; David Check; Cari M Kitahara
Journal:  JAMA       Date:  2017-04-04       Impact factor: 56.272

Review 4.  O-GlcNAc in cancer biology.

Authors:  Zhiyuan Ma; Keith Vosseller
Journal:  Amino Acids       Date:  2013-07-09       Impact factor: 3.520

5.  Enzymatic addition of O-GlcNAc to nuclear and cytoplasmic proteins. Identification of a uridine diphospho-N-acetylglucosamine:peptide beta-N-acetylglucosaminyltransferase.

Authors:  R S Haltiwanger; G D Holt; G W Hart
Journal:  J Biol Chem       Date:  1990-02-15       Impact factor: 5.157

6.  Purification and characterization of an O-GlcNAc selective N-acetyl-beta-D-glucosaminidase from rat spleen cytosol.

Authors:  D L Dong; G W Hart
Journal:  J Biol Chem       Date:  1994-07-29       Impact factor: 5.157

Review 7.  Molecular pathogenesis and mechanisms of thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Nat Rev Cancer       Date:  2013-03       Impact factor: 60.716

Review 8.  Thyroid cancer.

Authors:  Tobias Carling; Robert Udelsman
Journal:  Annu Rev Med       Date:  2013-11-20       Impact factor: 13.739

9.  Papillary thyroid carcinoma: differential diagnosis and prognostic values of its different variants: review of the literature.

Authors:  Rogelio Gonzalez-Gonzalez; Ronell Bologna-Molina; Ramón Gil Carreon-Burciaga; Marcelo Gómezpalacio-Gastelum; Nelly Molina-Frechero; Sirced Salazar-Rodríguez
Journal:  ISRN Oncol       Date:  2011-12-06

Review 10.  Papillary Thyroid Cancer-Aggressive Variants and Impact on Management: A Narrative Review.

Authors:  Andrés Coca-Pelaz; Jatin P Shah; Juan C Hernandez-Prera; Ronald A Ghossein; Juan P Rodrigo; Dana M Hartl; Kerry D Olsen; Ashok R Shaha; Mark Zafereo; Carlos Suarez; Iain J Nixon; Gregory W Randolph; Antti A Mäkitie; Luiz P Kowalski; Vincent Vander Poorten; Alvaro Sanabria; Orlando Guntinas-Lichius; Ricard Simo; Peter Zbären; Peter Angelos; Avi Khafif; Alessandra Rinaldo; Alfio Ferlito
Journal:  Adv Ther       Date:  2020-06-01       Impact factor: 3.845

View more
  6 in total

Review 1.  O-GlcNAcylation regulation of cellular signaling in cancer.

Authors:  Lorela Ciraku; Emily M Esquea; Mauricio J Reginato
Journal:  Cell Signal       Date:  2021-11-17       Impact factor: 4.315

2.  Histone Acetylation Regulator-Mediated Acetylation Patterns Define Tumor Malignant Pathways and Tumor Microenvironment in Hepatocellular Carcinoma.

Authors:  Yuyan Xu; Wei Liao; Qiong Luo; Dinghua Yang; Mingxin Pan
Journal:  Front Immunol       Date:  2022-01-25       Impact factor: 7.561

Review 3.  Posttranslational Modifications in Thyroid Cancer: Implications for Pathogenesis, Diagnosis, Classification, and Treatment.

Authors:  Jordan M Broekhuis; Benjamin C James; Richard D Cummings; Per-Olof Hasselgren
Journal:  Cancers (Basel)       Date:  2022-03-22       Impact factor: 6.639

Review 4.  O-GlcNAcylation and Its Role in Cancer-Associated Inflammation.

Authors:  Muzi Ouyang; Changmeng Yu; Xiaolian Deng; Yingyi Zhang; Xudong Zhang; Fangfang Duan
Journal:  Front Immunol       Date:  2022-04-01       Impact factor: 8.786

Review 5.  O-GlcNAcylation: an important post-translational modification and a potential therapeutic target for cancer therapy.

Authors:  Qingsong Lu; Xiaozhen Zhang; Tingbo Liang; Xueli Bai
Journal:  Mol Med       Date:  2022-09-14       Impact factor: 6.376

Review 6.  Metabolite-derived protein modifications modulating oncogenic signaling.

Authors:  Yawen Liu; Anke Vandekeere; Min Xu; Sarah-Maria Fendt; Patricia Altea-Manzano
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.